Cargando…
Clinical potential of brodalumab in the management of psoriasis: the evidence to date
Brodalumab is an anti-IL-17 receptor monoclonal antibody currently in development for the treatment of moderate-to-severe plaque psoriasis. With many systemic psoriasis therapies to choose from, and several newer agents in development, physicians need up to date evidence for the use of these drugs....
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5683110/ https://www.ncbi.nlm.nih.gov/pubmed/29387580 http://dx.doi.org/10.2147/PTT.S49996 |